Neuromuscular disease research involves a number of local studies as well as national multisite sponsored trials that evaluate treatments for neuromuscular conditions.

Gillette played a key role in the clinical trials and breakthrough research for the development of Spinraza™ (nusinersen) a drug to treat spinal muscular atrophy (SMA). The drug was recently approved by the FDA, making it the first-ever FDA-approved therapy for SMA.

This research includes the following conditions: